Chickenpox clinical trials
The registry lists 180 studies for Chickenpox across more than 10 countries. 28 are recruiting or about to start. 94 of them are mainly about Chickenpox (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Chickenpox studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (34) · Merck Sharp & Dohme LLC (28) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (17) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Sanofi Pasteur, a Sanofi Company (6) · University of Colorado, Denver (4) · Changchun Keygen Biological Products Co., Ltd. (3) · Suzhou Abogen Biosciences Co., Ltd. (3)
What is being tested here
Drugs under test in Chickenpox studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age · Phase 3 · GlaxoSmithKline
- Dec 2026A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age · Phase 3 · GlaxoSmithKline
- Dec 2026A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age · Phase 3 · GlaxoSmithKline
- Feb 2027SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years · Phase 3 · SK Bioscience Co., Ltd.
- Aug 2027A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years · Phase 3 · GC Biopharma Corp
- Oct 2027Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above · Phase 3 · Suzhou Abogen Biosciences Co., Ltd.
- Dec 2026Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation · Oriol Manuel
- Jan 2027Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above · Aribio Lab Co., Ltd.
- Jan 2027Evaluation of the Anti-VZV Vaccine Response of Patients With Immune-mediated Systemic Inflammatory Diseases Vaccinated in the Care Setting · Assistance Publique - Hôpitaux de Paris
- Jan 2027Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study · Susanne Dam Nielsen, MD, DMSc
Who these studies take
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger. 12 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 13 (81%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 6 (38%) | 6 (38%) |
| 18 | 4 (25%) | 4 (25%) |
| 30 | 3 (19%) | 3 (19%) |
| 40 | 5 (31%) | 5 (31%) |
| 50 | 5 (31%) | 5 (31%) |
| 65 | 4 (25%) | 4 (25%) |
| 75 | 4 (25%) | 4 (25%) |
| 85 | 3 (19%) | 3 (19%) |
Across all 180 studies, recruiting or not: 71% stop at 75 or younger and 67% at 65; 71% take children; 1% are for women only and 0% for men only; 77% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Chickenpox studies take
Of 39 phase 3 interventional studies under Chickenpox, half reached primary completion within 13 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 17 mo7–38 · 17 studies | — | — |
| Phase 3 | 13 mo9–24 · 39 studies | 12 mo8–15 · 35 studies | — |
| Phase 4 | 4 mo2–22 · 14 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 180. Browse all 180 → or search them.
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 YearsRecruitingNCT07415252Phase 34 countries
- Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled TrialNot yet recruitingNCT07818356Phase 41 country
- Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveRecruitingNCT07817108Phase 31 country
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 36 countries
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 31 country
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese ChildrenNot yet recruitingNCT07473427Phase 31 country
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgeRecruitingNCT06855160Phase 37 countries
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of AgeRecruitingNCT06806137Phase 32 countries
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeRecruitingNCT06693895Phase 38 countries
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeRecruitingNCT06740630Phase 311 countries
- A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 YearsRecruitingNCT07054099Phase 31 country
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant RecipientsEnrolling by invitationNCT06162494Phase 41 country
- Second Dose of Varicella Vaccine in Healthy ChildrenRecruitingNCT07475000Phase 31 country
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ TransplantationNot yet recruitingNCT07443709Phase 21 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsNot yet recruitingNCT07205796Phase 2
- Evaluation of the Anti-VZV Vaccine Response of Patients With Immune-mediated Systemic Inflammatory Diseases Vaccinated in the Care SettingRecruitingNCT070470531 country
- Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and OlderRecruitingNCT06874842Phase 11 country
- Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP VaccineNot yet recruitingNCT06891872Phase 41 country
- Correlation of Protection Against Varicella in an Exploratory StudyNot yet recruitingNCT06482216
- An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella VaccineEnrolling by invitationNCT06484686Phase 41 country
- An Immunity Persistence Study of Live Attenuated Varicella VaccineEnrolling by invitationNCT05095701Phase 41 country
- A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult SubjectsyRecruitingNCT06068608Phase 11 country
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldEnrolling by invitationNCT05015686Phase 31 country
- Pediatric and Ambulatory Research in Infectious DiseasesRecruitingNCT044714931 country
- Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella VaccinationRecruitingNCT05422508Phase 21 country
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingNCT05952505Phase 41 country
- Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation RecipientsRecruitingNCT00492739Phase 2/31 country
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and AboveActive, not recruitingNCT07481604Phase 21 country
- Herpes Virus Infections in Kidney Transplant PatientsActive, not recruitingNCT056049111 country
- Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant StudyActive, not recruitingNCT055325401 country
- Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveActive, not recruitingNCT07285265Phase 11 country
- Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveActive, not recruitingNCT07285278Phase 21 country
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy AdultsTerminatedNCT05703607Phase 1/21 country
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and NeuroblastomaActive, not recruitingNCT01953900Phase 11 country
- A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsCompletedNCT06375512Phase 12 countries
- A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and OlderActive, not recruitingNCT07311148Phase 21 country
- Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing ProgramCompletedNCT069013621 country
- Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderActive, not recruitingNCT05304351Phase 21 country
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 24 countries
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 25 countries
- Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 YearsActive, not recruitingNCT06409494Phase 11 country
- Study on Booster Immunization With Varicella Vaccine at Different IntervalsCompletedNCT06994052Phase 41 country
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)CompletedNCT06987942Phase 41 country
- A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 YearsActive, not recruitingNCT06335849Phase 11 country
- Zoster Eye Disease StudyCompletedNCT03134196Phase 42 countries
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of AgeCompletedNCT05084508Phase 26 countries
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the PhilippinesCompletedNCT06314724Phase 31 country
- A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 YearsCompletedNCT05991427Phase 11 country
- Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 YearsCompletedNCT06614816Phase 31 country